PledPharma

PledPharma develops new medicines that protects against dose-limiting side effects during cancer therapy with cytostatic drugs, without diminishing the anticancer effect. The medicine is based on Low Molecular weight Enzyme Mimetics (LowMEM). The company's first candidate PP-095 is now being tested on cancer patients in clinical phase II trials.

www.pledpharma.se

LEAD i Östergötland AB
LINKÖPING Mjärdevi Science Park, Teknikringen 7, SE-583 30 Linköping, SWEDEN | TEL +46-13-21 01 10 | FAX +46-13-21 01 29
NORRKÖPING Norrköping Science Park, Laxholmstorget 3, SE-602 21 Norrköping, SWEDEN | TEL +46-11-12 58 50

| www.leadincubator.se
Created by Svarteld/Revide